Program
TLL-018
A development code. Also written as “TLL-018 tablets”, “TLL018 tablets” and “TLL-018 extended-release tablet”.
Its studies are mostly in Arthritis, Rheumatoid · Chronic Urticaria · Dermatitis, Atopic · Psoriasis · Colitis, Ulcerative, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Highlightll Pharmaceutical | 126 open or running | phase 3since Aug 25, 2023 | Nov 15, 2021 | Dec 31, 2026phase 3 · NCT06887127 |
| TLL Pharmaceutical | 10 open or running | phase 2since Nov 5, 2021 | Nov 5, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 5, 2021First study: phase 2 study in Colitis, UlcerativeNew to TLL PharmaceuticalTLL Pharmaceutical · NCT05121402 · United States
- Nov 15, 2021Hangzhou Highlightll Pharmaceutical's first study: phase 2 study in Arthritis, RheumatoidNew to Hangzhou Highlightll PharmaceuticalHangzhou Highlightll Pharmaceutical · NCT05133297 · 101 enrolled · China
- Apr 7, 2022Phase 1 study in Moderate to Severe Plaque PsoriasisHangzhou Highlightll Pharmaceutical · NCT05342428 · 73 enrolled · China
- May 10, 2022Phase 1 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT05373355 · 41 enrolled · China
- Mar 6, 2023Phase 2 study in Plaque PsoriasisHangzhou Highlightll Pharmaceutical · NCT05772520 · 82 enrolled · United States
- Jul 5, 2023Phase 1 study in Dermatitis, AtopicHangzhou Highlightll Pharmaceutical · NCT05945810 · 28 enrolled · China
- Aug 25, 2023Phase 3 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT06020144 · 459 enrolled · China
- Apr 29, 2024Phase 3 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT06396026 · 440 enrolled · China
- Mar 14, 2025Phase 3 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT06887127 · 350 enrolled · China
- Jun 18, 2026Phase 2 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT07665996 · 36 planned · China
- Jul 31, 2026Phase 2 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT07748728 · 90 planned · China
- Aug 9, 2026Phase 2 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT07764003 · 140 planned
- Aug 21, 2026Phase 3 study in Dermatitis, AtopicHangzhou Highlightll Pharmaceutical · NCT07784816 · 390 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT06887127
- Jul 31, 2027Primary completion: phase 2 study in Arthritis, RheumatoidHangzhou Highlightll Pharmaceutical · NCT07748728
- Dec 31, 2027Primary completion: phase 2 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT07764003
- Dec 31, 2027Primary completion: phase 2 study in Chronic UrticariaHangzhou Highlightll Pharmaceutical · NCT07665996
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07784816Dermatitis, Atopic · China | 3 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical | Sep 30, 2029 | 390 |
| NCT07764003Chronic Urticaria | 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical | Dec 31, 2027 | 140 |
| NCT07748728Arthritis, Rheumatoid · China | 2 | By invitation | Hangzhou Highlightll Pharmaceutical | Jul 31, 2027 | 90 |
| NCT07665996Chronic Urticaria · China | 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical | Dec 31, 2027 | 36 |
| NCT06887127Arthritis, Rheumatoid · China | 3 | Active, not recruiting | Hangzhou Highlightll Pharmaceutical | Dec 31, 2026 | 350 |
| NCT06396026Chronic Urticaria · China | 3 | Active, not recruiting | Hangzhou Highlightll Pharmaceutical | Oct 23, 2025 | 440 |
| NCT06020144Arthritis, Rheumatoid · China | 3 | Completed | Hangzhou Highlightll Pharmaceutical | Jan 15, 2026 | 459 |
| NCT05945810Dermatitis, Atopic · China | 1 | Completed | Hangzhou Highlightll Pharmaceutical | Aug 28, 2023 | 28 |
| NCT05772520Plaque Psoriasis · United States | 2 | Completed | Hangzhou Highlightll Pharmaceutical | Dec 1, 2024 | 82 |
| NCT05373355Chronic Urticaria · China | 1 | Completed | Hangzhou Highlightll Pharmaceutical | Sep 7, 2023 | 41 |
| NCT05342428Moderate to Severe Plaque Psoriasis · China | 1 | Completed | Hangzhou Highlightll Pharmaceutical | Aug 30, 2023 | 73 |
| NCT05133297Arthritis, Rheumatoid · China | 2 | Completed | Hangzhou Highlightll Pharmaceutical | Dec 19, 2022 | 101 |
| NCT05121402Colitis, Ulcerative · United States | 2 | Withdrawn | TLL Pharmaceutical | Jul 1, 2023 | 0 |
How it is read
Names in the registry
- “TLL-018”, 8 entries
- “TLL-018 tablets”, 6 entries
- “TLL018 tablets”, 3 entries
- “TLL-018 extended-release tablet”, 1 entry
- “TLL-018 immediate-release tablet”, 1 entry
Codes read as this program: TLL018.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 4 studies
- Chronic Urticaria, 4 studies
- Dermatitis, Atopic, 2 studies
- Psoriasis, 2 studies
- Colitis, Ulcerative, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.